WO2005034735A3 - Method for assessing the risk for insulin resistant diabetes and/or heart disease - Google Patents

Method for assessing the risk for insulin resistant diabetes and/or heart disease Download PDF

Info

Publication number
WO2005034735A3
WO2005034735A3 PCT/US2004/033375 US2004033375W WO2005034735A3 WO 2005034735 A3 WO2005034735 A3 WO 2005034735A3 US 2004033375 W US2004033375 W US 2004033375W WO 2005034735 A3 WO2005034735 A3 WO 2005034735A3
Authority
WO
WIPO (PCT)
Prior art keywords
pld
gdi
risk
levels
gpi
Prior art date
Application number
PCT/US2004/033375
Other languages
French (fr)
Other versions
WO2005034735A2 (en
Inventor
Mark Deeg
Original Assignee
Advanced Res & Tech Inst
Mark Deeg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Res & Tech Inst, Mark Deeg filed Critical Advanced Res & Tech Inst
Publication of WO2005034735A2 publication Critical patent/WO2005034735A2/en
Publication of WO2005034735A3 publication Critical patent/WO2005034735A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Levels of the protein glycosylphosphatidylinositol specific phospholipase D (GPI-PLD) correlate with an increased risk of developing Type II diabetes and heart disease. Diagnostic tests and test kits are used to identify individuals at elevated risk for developing these conditions based on abnormal levels of GDIPLD in samples collected from patients. A method of identifying compounds that can lower the level of glycosylphosphatidylinositol specific phospholipase D (GPI-PLD in at risk patients is also disclosed. Compounds that alter the amount of GPI-PLD, such as the compound Wy 14, 643 are also disclosed. One of the methods for measuring GDI-PLD levels in various samples are antibody based methods using antibody raised in animals to the protein GDI-PLD. Still another method for measuring GDI-PLD levels involves measuring the activity of GDI-PLD in various samples thought to include GDI-PLD by following the conversion of at least one GDI-PLD substrate or an analogues of at least one GDI-PLD substrate.
PCT/US2004/033375 2003-10-08 2004-10-08 Method for assessing the risk for insulin resistant diabetes and/or heart disease WO2005034735A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50966503P 2003-10-08 2003-10-08
US60/509,665 2003-10-08

Publications (2)

Publication Number Publication Date
WO2005034735A2 WO2005034735A2 (en) 2005-04-21
WO2005034735A3 true WO2005034735A3 (en) 2005-12-15

Family

ID=34435006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/033375 WO2005034735A2 (en) 2003-10-08 2004-10-08 Method for assessing the risk for insulin resistant diabetes and/or heart disease

Country Status (1)

Country Link
WO (1) WO2005034735A2 (en)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DEEG M.A. AND BOWEN R.F. ET AL: "Midportion antibodies stimulate glycosylphosphatidylinositol-specific phospholipase D activity.", ARCH BIOCHEM BIOPHYS., vol. 370, no. 2, 15 October 1999 (1999-10-15), pages 278 - 284, XP002992292 *
O'BRIEN K.D. ET AL: "Glycosylphosphatidylinositol-specific phospholipase D is expressed by macrophages in human atherosclerosis and colocalizes with oxidation epitopes.", CIRCULATION., vol. 99, no. 22, 8 June 1999 (1999-06-08), pages 2876 - 2882, XP002185518 *
SCHOFIELD J.N. ET AL: "Insulin Reduces Serum Glycosylphosphatidylinositol Phospholipase D Levels in Human Type I Diabetic Patients and Streptozotocin Diabetic Rats.", MOL GEN METAB., vol. 75, no. 2, 6 February 2002 (2002-02-06), pages 154 - 161, XP002992291 *

Also Published As

Publication number Publication date
WO2005034735A2 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
Tonetti et al. Implementation of the new classification of periodontal diseases: Decision‐making algorithms for clinical practice and education
Choudhary et al. Frequency of biochemical hypoglycaemia in adults with type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring
Vitale et al. Unawareness of dyskinesias in Parkinson's and Huntington's diseases
Bansal et al. Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting
AU4469300A (en) Nmr-method for determining the risk of developing type 2 diabetes
Virvidaki et al. Swallowing and aspiration risk: a critical review of non instrumental bedside screening tests
HK1113160A1 (en) Methods for the diagnosis of dementia and other neurological disorders
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
Price Point-of-care testing in diabetes mellitus
EP0962878A3 (en) Reflex algorithm for early and cost effective diagnosis of myocardial infarctions suitable for automated diagnostic platforms
EP2770328A3 (en) Method to diagnose pancreatic cancer
NO20050186L (en) Oligosaccharide Biomarkers for Mucopolysaccharides and Other Related Disorders
Wunsch et al. Normalization of the psychometric hepatic encephalopathy score in Polish population. A prospective, quantified electroencephalography study
WO2005071407A3 (en) Methods of diagnosing acute coronary syndrome by measuring urotensin ii
RU2008103988A (en) METHOD FOR DIAGNOSIS OF MULTIPLE SCLEROSIS
EP1785889A3 (en) Assessment of reactivity by EEG analysis
Levinson Complementarily of urine analysis and serum free light chain assay for assessing response treatment response: illustrated by three case examples
JP2019509500A (en) Diagnosis of mild cognitive impairment (MCI), prediction of onset of Alzheimer's disease (AD) type dementia, and screening and monitoring of drugs for treatment of MCI or prevention of dementia development
WO2005034735A3 (en) Method for assessing the risk for insulin resistant diabetes and/or heart disease
CA3016500C (en) Direct infrared analysis of post-translational modification of proteins
Paxton et al. Urinary nicotine concentration as a function of time since last cigarette: Implications for detecting faking in smoking clinics
Shoji et al. Electrocardiographic left atrial abnormality and B-Type natriuretic peptide in a general Japanese population: NIPPON DATA2010
Garvin et al. A critical examination of gamma-glutamyl transpeptidase as a biochemical marker for alcohol abuse
EP1866649A1 (en) Chemiluminescent method and device for evaluating the in vivo functional state of phagocytes
Bheemavarapu et al. Image-based Tracking of Immunoassay Reaction Progress in Quantitative Lateral Flow Kits

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase